It took an extra month, but the European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Rigel Pharmaceuticals’ (NASDAQ:RIGL) Tavlesse (fostamatinib) for the treatment of primary thrombocytopenia (low blood platelets) in adult patients who have not responded to other treatments.
In October, CHMP indicated a “positive trend vote.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.